News & Updates

Show Multimedia Only

Tenofovir regimen with levonorgestrel vaginal ring safe, effective in women

18 Oct 2022

A 90-day tenofovir (TFV) regimen combined with a levonorgestrel (LNG) intravaginal ring (IVR), which elutes the drug continuously or cyclically, is safe for use in women and can effectively prevent unintended pregnancies, a recent phase I study has found.

Tenofovir regimen with levonorgestrel vaginal ring safe, effective in women

18 Oct 2022

Gabapentin offers pain relief during second-trimester surgical abortion

17 Oct 2022

Preoperative administration of gabapentin helps reduce intraoperative pain in women undergoing second-trimester surgical abortion, leading to improved satisfaction with pain management, as shown in a randomized, controlled, double-blind trial.

Gabapentin offers pain relief during second-trimester surgical abortion

17 Oct 2022

IVF tied to maternal morbidity

17 Oct 2022

Achieving pregnancy through in vitro fertilization (IVF) appears to increase the risk of severe maternal morbidity both during singleton or multiple pregnancies, a recent Korea study has found.

IVF tied to maternal morbidity

17 Oct 2022

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

New drug applications approved by US FDA as of 01 - 15 October 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (01 - 15 October 2022)

15 Oct 2022

Prexasertib works in select patients with recurrent ovarian cancer

14 Oct 2022

CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.

Prexasertib works in select patients with recurrent ovarian cancer

14 Oct 2022

Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer

12 Oct 2022 by

In the second interim overall survival (OS) analysis of the phase III TROPiCS-02 study, sacituzumab govitecan (SG) – a first-in-class Trop-2*-directed antibody-drug conjugate approved for triple-negative metastatic breast cancer (mBC) with ≥2 prior therapies (≥1 in the metastatic setting) – conferred an OS benefit for pretreated HR+/HER2– mBC, compared with treatment of physician’s choice (TPC**).

Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer

12 Oct 2022

Donor sperm use in IVF not linked to adverse perinatal outcomes

10 Oct 2022

In vitro fertilization (IVF) pregnancies conceived with donor sperm are not necessarily at increased risk of adverse perinatal outcomes compared with similar pregnancies conceived with partner sperm, according to a study.